Ferrari, A. J. et al. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disord. 18, 440–450 (2016).
Polderman, T. J. C. et al. Meta-analysis of the heritability of human traits based on fifty years of twin studies. Nat. Genet. 47, 702–709 (2015).
Stahl, E. A. et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat. Genet. 51, 793–803 (2019).
Brainstorm Consortium. et al. Analysis of shared heritability in common disorders of the brain. Science 360, eaap8757 (2018).
Mullins, N. et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology.Nat. Genet. 53, 817–829 (2021).
Charney, A. W. et al. Contribution of rare copy number variants to bipolar disorder risk is limited to schizoaffective cases. Biol. Psychiatry 86, 110–119 (2019).
Ganna, A. et al. Quantifying the impact of rare and ultra-rare coding variation across the phenotypic spectrum. Am. J. Hum. Genet. 102, 1204–1211 (2018).
J., A., Crow, J. F. & Kimura, M. An introduction to population genetics theory. Popul. (Fr. Ed.). 26, 977 (1971).
Kryukov, G. V., Pennacchio, L. A. & Sunyaev, S. R. Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. Am. J. Hum. Genet. 80, 727–739 (2007).
Power, R. A. et al. Fecundity of patients with schizophrenia, autism, bipolar disorder, depression, anorexia nervosa, or substance abuse vs their unaffected siblings. JAMA Psychiatry 70, 22–30 (2013).
American Psychiatric Association, Task Force on DSM-IV. DSM-IV Sourcebook (American Psychiatric Publishing, 1998).
Janca, A., Ustün, T. B., Early, T. S. & Sartorius, N. The ICD-10 symptom checklist: a companion to the ICD-10 classification of mental and behavioural disorders. Soc. Psychiatry Psychiatr. Epidemiol. 28, 239–242 (1993).
Malaspina, D. et al. Schizoaffective disorder in the DSM-5. Schizophr. Res. 150, 21–25 (2013).
O’Connell, K. S. & Coombes, B. J. Genetic contributions to bipolar disorder: current status and future directions.Psychol. Med. 51, 2156–2167 (2021).
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (American Psychiatric Publishing, 2013).
Husson, T. et al. Identification of potential genetic risk factors for bipolar disorder by whole-exome sequencing. Transl. Psychiatry 8, 268 (2018).
Sul, J. H. et al. Contribution of common and rare variants to bipolar disorder susceptibility in extended pedigrees from population isolates. Transl. Psychiatry 10, 74 (2020).
Jia, X. et al. Investigating rare pathogenic/likely pathogenic exonic variation in bipolar disorder. Mol. Psychiatry 26, 5239–5250 (2021).
Cruceanu, C. et al. Rare susceptibility variants for bipolar disorder suggest a role for G protein-coupled receptors. Mol. Psychiatry 23, 2050–2056 (2018).
Genovese, G. et al. Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. Nat. Neurosci. 19, 1433–1441 (2016).
Singh, T. et al. The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability. Nat. Genet. 49, 1167–1173 (2017).
McLaren, W. et al. The Ensembl variant effect predictor. Genome Biol. 17, 122 (2016).
Singh, T. et al. Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature https://doi.org/10.1038/s41586-022-04556-w (2022).
Samocha, K. E., Kosmicki, J. A. & Karczewski, K. J. Regional missense constraint improves variant deleteriousness prediction. Preprint at bioRxiv https://doi.org/10.1101/148353 (2017).
Aguet, F. et al. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369, 1318–1330 (2020).
Finucane, H. K. et al. Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. Nat. Genet. 50, 621–629 (2018).
Hibar, D. P. et al. Subcortical volumetric abnormalities in bipolar disorder. Mol. Psychiatry 21, 1710–1716 (2016).
Ganna, A. et al. Ultra-rare disruptive and damaging mutations influence educational attainment in the general population. Nat. Neurosci. 19, 1563–1565 (2016).
Cotney, J. et al. The autism-associated chromatin modifier CHD8 regulates other autism risk genes during human neurodevelopment. Nat. Commun. 6, 6404 (2015).
Weyn-Vanhentenryck, S. M. et al. HITS-CLIP and integrative modeling define the Rbfox splicing-regulatory network linked to brain development and autism. Cell Rep. 6, 1139–1152 (2014).
Sanders, S. J. et al. Insights into autism spectrum disorder genomic architecture and biology from 71 risk loci. Neuron 87, 1215–1233 (2015).
Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium & Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium. Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes. Cell 173, 1705–1715 (2018).
Trubetskoy, V. et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature https://doi.org/10.1038/s41586-022-04434-5 (2022).
Freland, L. & Beaulieu, J.-M. Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front. Mol. Neurosci. 5, 14 (2012).
Kishore, B. K. & Ecelbarger, C. M. Lithium: a versatile tool for understanding renal physiology. Am. J. Physiol. Ren. Physiol. 304, F1139–F1149 (2013).
Jope, R. S. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol. Sci. 24, 441–443 (2003).
Satterstrom, F. K. et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of Autism. Cell 180, 568–584.e23 (2020).
Satterstrom, F. K. et al. Autism spectrum disorder and attention deficit hyperactivity disorder have a similar burden of rare protein-truncating variants. Nat. Neurosci. 22, 1961–1965 (2019).
Epi25 Collaborative. Ultra-rare genetic variation in the epilepsies: a whole-exome sequencing study of 17,606 individuals. Am. J. Hum. Genet. 105, 267–282 (2019).
Firth, H. V. et al. DECIPHER: database of chromosomal imbalance and phenotype in humans using ensembl resources. Am. J. Hum. Genet. 84, 524–533 (2009).
Tanji, C. et al. A-kinase anchoring protein AKAP220 binds to glycogen synthase kinase-3beta (GSK-3beta) and mediates protein kinase A-dependent inhibition of GSK-3beta. J. Biol. Chem. 277, 36955–36961 (2002).
Beurel, E., Grieco, S. F. & Jope, R. S. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol. Ther. 148, 114–131 (2015).
Howrigan, D. P. et al. Exome sequencing in schizophrenia-affected parent-offspring trios reveals risk conferred by protein-coding de novo mutations. Nat. Neurosci. 23, 185–193 (2020).
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. 57, 289–300 (1995).
Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinforma. 43, 11.10.1–11.10.33 (2013).
DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011).
Ng, P. C. & Henikoff, S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812–3814 (2003).
Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248–249 (2010).
Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).
Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 47, D886–D894 (2019).
Chen, C.-Y. et al. Genetic validation of bipolar disorder identified by automated phenotyping using electronic health records. Transl. Psychiatry 8, 86 (2018).
Murphy, S. et al. Instrumenting the health care enterprise for discovery research in the genomic era. Genome Res. 19, 1675–1681 (2009).
Wing, J. SCAN (Schedules for Clinical Assessment in Neuropsychiatry) and the PSE (Present State Examination) Tradition. Mental Health Outcome Measures 123–130 (Springer, 1996).
McGuffin, P., Farmer, A. & Harvey, I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch. Gen. Psychiatry 48, 764–770 (1991).